SOPHiA GENETICSSOPH
SOPH
About: Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
Employees: 423
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
115% more call options, than puts
Call options by funds: $28K | Put options by funds: $13K
39% more capital invested
Capital invested by funds: $55.5M [Q4 2024] → $77.2M (+$21.7M) [Q1 2025]
7.27% more ownership
Funds ownership: 27.52% [Q4 2024] → 34.79% (+7.27%) [Q1 2025]
11% less funds holding
Funds holding: 36 [Q4 2024] → 32 (-4) [Q1 2025]
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Research analyst outlook
We haven’t received any recent analyst ratings for SOPH.
Financial journalist opinion
Neutral
Seeking Alpha
1 month ago
SOPHiA GENETICS SA (SOPH) Q1 2025 Earnings Call Transcript
SOPHiA GENETICS SA. (NASDAQ:SOPH ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Kellen Sanger - Head, Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer Ross Muken - President George Cardoza - Chief Financial Officer Conference Call Participants William Bonello - Craig-Hallum Conor McNamara - RBC Capital Markets Subbu Nambi - Guggenheim Operator Good morning, ladies and gentlemen, and welcome to the SOPHiA GENETICS Q1 2025 Earnings Call.
Negative
Zacks Investment Research
1 month ago
SOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue Estimates
SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.21 per share a year ago.
Neutral
PRNewsWire
1 month ago
SOPHiA GENETICS Reports First Quarter 2025 Results
BOSTON and ROLLE, Switzerland , May 6, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Revenue was $17.8 million, up 13% year-over-year or 15% on a constant currency basis Gross margin was 68.7% on a reported basis and 75.7% on an adjusted basis, up from 65.9% and 70.5% in the prior year period, respectively IFRS net loss increased 27% year-over-year to $17.4 million (including a net foreign exchange P&L impact of $5.2 million), and adjusted EBITDA loss improved 24% year-over-year to $9.8 million The company reiterates full-year guidance of revenue between $72 million and $76 million and adjusted EBITDA loss between $35 million and $39 million "We started the year strong with year-over-year revenue growth of 13%, or 15% on a constant currency basis, as the large amount of new business signed in 2024 begins to ramp," said Jurgi Camblong, PhD.
Neutral
PRNewsWire
1 month ago
SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR
BOSTON and ROLLE, Switzerland , April 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ globally. Building on the initial collaboration announced in October 2024 , this new phase will extend the test's reach to a total of 30 clinical institutions worldwide in 2025.
Neutral
PRNewsWire
1 month ago
SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025
BOSTON and ROLLE, Switzerland , April 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter 2025 before U.S. markets open on Tuesday, May 6, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.
Neutral
PRNewsWire
2 months ago
Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities
The partnership integrates advanced AI-driven analytics and clinical trial solutions, empowering biopharma companies to accelerate drug development and deliver targeted therapies faster. BETHESDA, Md.
Positive
Zacks Investment Research
2 months ago
SOPHiA GENETICS (SOPH) Upgraded to Buy: What Does It Mean for the Stock?
SOPHiA GENETICS (SOPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
PRNewsWire
2 months ago
SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTC
BOSTON, MA and ROLLE, Switzerland , March 18, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, has reached a historic milestone: more than two million patients genomic profiles analyzed on the AI-powered analytics Platform SOPHiA DDM™. This achievement solidifies SOPHiA GENETICS as the gold-standard provider of actionable insights for patient care, applying AI capabilities shaped by an unmatched dataset of diverse, real-world patient data.
Neutral
Seeking Alpha
3 months ago
SOPHiA GENETICS SA (SOPH) Q4 2024 Earnings Call Transcript
SOPHiA GENETICS SA (NASDAQ:SOPH ) Q4 2024 Earnings Call March 4, 2025 8:00 AM ET Company Participants Kellen Sanger - Head, Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer Ross Muken - President George Cardoza - Chief Financial Officer Conference Call Participants Subbu Nambi - Guggenheim Mark Massaro - BTIG Tejas Savant - Morgan Stanley Bill Bonello - Craig-Hallum Operator Good morning. My name is Liway and I'll be your conference operator today.
Negative
Zacks Investment Research
3 months ago
SOPHiA GENETICS SA (SOPH) Reports Q4 Loss, Tops Revenue Estimates
SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.37 per share a year ago.
Charts implemented using Lightweight Charts™